RAB1B

Summary

RAB1B (RAB1B, member RAS oncogene family, HGNC:18370) is a protein-coding gene on chromosome 11q13.2, encoding Ras-related protein Rab-1B (Q9H0U4). The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes. It is a selective cancer dependency (DepMap: 13.0% of cell lines).

Members of the RAB protein family, such as RAB1B, are low molecular mass monomeric GTPases localized on the cytoplasmic surfaces of distinct membrane-bound organelles. RAB1B functions in the early secretory pathway and is essential for vesicle transport between the endoplasmic reticulum (ER) and Golgi (Chen et al., 1997 [PubMed 9030196]; Alvarez et al., 2003 [PubMed 12802079]).

Source: NCBI Gene 81876 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 23 total
• Cancer dependency (DepMap): dependent in 13.0% of screened cell lines
• MANE Select transcript: NM_030981

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18370
Approved symbol	RAB1B
Name	RAB1B, member RAS oncogene family
Location	11q13.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000174903
Ensembl biotype	protein_coding
OMIM	612565
Entrez	81876

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 5 protein_coding

ENST00000311481, ENST00000527397, ENST00000884282, ENST00000884283, ENST00000884284

RefSeq mRNA: 1 — MANE Select: NM_030981 NM_030981

CCDS: CCDS31613

Canonical transcript exons

ENST00000311481 — 6 exons

Exon	Start	End
ENSE00001189419	66276044	66277492
ENSE00001189431	66272365	66272460
ENSE00001189438	66272157	66272252
ENSE00001189443	66271797	66271869
ENSE00002143744	66268639	66268693
ENSE00002712711	66275804	66275935

Expression profiles

Bgee: expression breadth ubiquitous, 286 present calls, max score 98.58.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 96.0443 / max 419.9149, expressed in 1823 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
115305	80.0290	1821
115304	15.1508	1796
115306	0.8247	426
115303	0.0398	14

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	98.58	gold quality
lower esophagus mucosa	UBERON:0035834	98.39	gold quality
lower esophagus	UBERON:0013473	98.34	gold quality
lower esophagus muscularis layer	UBERON:0035833	98.34	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	98.32	gold quality
apex of heart	UBERON:0002098	98.26	gold quality
skin of leg	UBERON:0001511	98.24	gold quality
body of stomach	UBERON:0001161	98.19	gold quality
gastrocnemius	UBERON:0001388	98.16	gold quality
transverse colon	UBERON:0001157	98.15	gold quality
right adrenal gland	UBERON:0001233	98.14	gold quality
right coronary artery	UBERON:0001625	98.10	gold quality
right adrenal gland cortex	UBERON:0035827	98.10	gold quality
esophagus	UBERON:0001043	98.07	gold quality
skin of abdomen	UBERON:0001416	98.06	gold quality
left coronary artery	UBERON:0001626	98.06	gold quality
popliteal artery	UBERON:0002250	98.06	gold quality
tibial artery	UBERON:0007610	98.06	gold quality
left adrenal gland	UBERON:0001234	98.05	gold quality
muscle layer of sigmoid colon	UBERON:0035805	98.05	gold quality
right lung	UBERON:0002167	98.04	gold quality
granulocyte	CL:0000094	98.03	gold quality
thoracic aorta	UBERON:0001515	98.01	gold quality
left adrenal gland cortex	UBERON:0035825	98.01	gold quality
mucosa of stomach	UBERON:0001199	98.00	gold quality
ascending aorta	UBERON:0001496	97.99	gold quality
metanephros cortex	UBERON:0010533	97.99	gold quality
aorta	UBERON:0000947	97.98	gold quality
minor salivary gland	UBERON:0001830	97.98	gold quality
descending thoracic aorta	UBERON:0002345	97.98	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-8894	no	118.62
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

106 targeting RAB1B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-7845-5P	99.88	64.88	771
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-1321	99.84	65.30	1811
HSA-MIR-4739	99.84	65.25	1832
HSA-MIR-4756-5P	99.84	64.98	1809
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-6842-5P	99.80	67.54	1587
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-3150A-3P	99.76	64.44	1640
HSA-MIR-6763-5P	99.76	64.68	1767
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-3913-3P	99.74	66.53	938
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-5093	99.67	69.26	2291
HSA-MIR-3175	99.65	66.30	2031

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 13.0% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 22)

• These data support a model where Rab1b-GTP induces GBF1 recruitment at the ERES interface and at the Golgi complex where it is required for COPII/COPI exchange or COPI vesicle formation, respectively. (PMID:17429068)
• findings show that SidM from Legionella pneumophila could act as both a GDP-GTP exchange factor and GDP-dissociation inhibitor-displacement factor (GDF) for Rab1 (PMID:17947549)
• The authors demonstrate that Rab1b-activated GBF1 and ARF1 are involved in Ebolavirus virion formation, suggesting that both the COPII and COPI transport systems play a role in Ebolavirus VP40-mediated particle formation. (PMID:20164217)
• Antibacterial autophagy occurs at omegasomes and reveal that the Rab1 GTPase plays a crucial role in mammalian autophagy. (PMID:20980813)
• Rab1b is a key regulatory component of COPII dynamics and function. (PMID:21093099)
• Rab1a/b and Rab43, are important for herpes simplex virus 1 virion assembly (PMID:21680502)
• results indicate that the cellular localization of MTMR6 is regulated by Rab1B in the early secretory and autophagic pathways (PMID:23188820)
• The detailed molecular reaction mechanism of a complex between human Rab and RabGAP at the highest possible spatiotemporal resolution and in atomic detail, is described. (PMID:23236136)
• The crystal structure of the Rab1b-LepB complex. (PMID:23288104)
• Our results show, for the first time, that changes in Rab1b levels modulate gene transcription and strongly suggest that a Rab1b increase is required to elicit a secretory response. (PMID:23325787)
• RAB1B acts as a metastasis suppressor in triple-negative breast cancer by regulating the TGF-beta/SMAD signaling pathway and RAB1B may serve as a biomarker of prognosis and response to anti-tumor therapeutics for patients with triple-negative breast cancer. (PMID:25970785)
• RAB1B localization to the Golgi. (PMID:26977884)
• Survival analysis indicates that patients with overexpression of Rab1B or MMP9 have significantly worse overall survival and progression-free survival, but better response to chemotherapy than those with low expression of proteins, and that Rab1B is an independent prognostic factor for colorectal cancer patients. (PMID:28316326)
• In these Rab1B-depleted cells, ATG9A accumulated in intermediate membrane structures at autophagosome formation sites. These results indicate that Rab1B is involved in regulating the proper development of autophagosomes. (PMID:28522593)
• Rab1b differentially controls the secretion of apolipoproteins and of HCV. (PMID:29020629)
• ARF5 and Rab1b exhibit RNA-binding capacity, suggesting a role for domain 3 of the IRES in RNA localization into specific cellular compartments. (PMID:30655362)
• RAB1b interacts with TRAF3 to promote antiviral innate immunity. (PMID:31375559)
• Rab1-AMPylation by Legionella DrrA is allosterically activated by Rab1. (PMID:33469029)
• LINC00173 facilitates tumor progression by stimulating RAB1B-mediated PA2G4 and SDF4 secretion in nasopharyngeal carcinoma. (PMID:36606322)
• Circ_RBM23 knockdown suppresses chemoresistance, proliferation, migration and invasion of sorafenib-resistant HCC cells through miR-338-3p/RAB1B axis. (PMID:37075641)
• Dephosphocholination by Legionella effector Lem3 functions through remodelling of the switch II region of Rab1b. (PMID:37076474)
• MicroR-380-3p Reduces Sepsis-Induced Acute Kidney Injury via Regulating RAB1P to Restrain NF-kappaB Pathway. (PMID:38220171)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	rab1ab	ENSDARG00000029663
danio_rerio	rab1aa	ENSDARG00000052263
mus_musculus	Rab1b	ENSMUSG00000024870
rattus_norvegicus	Rab1b	ENSRNOG00000050510
rattus_norvegicus	Rab1b	ENSRNOG00000070897

Paralogs (68): RAB27B (ENSG00000041353), RAB27A (ENSG00000069974), RAB7A (ENSG00000075785), RABL2B (ENSG00000079974), RAB21 (ENSG00000080371), RAB10 (ENSG00000084733), RAB18 (ENSG00000099246), RAB36 (ENSG00000100228), IFT27 (ENSG00000100360), RAB40AL (ENSG00000102128), RAB11A (ENSG00000103769), RAB2A (ENSG00000104388), RAB3D (ENSG00000105514), RAB3A (ENSG00000105649), RAB5C (ENSG00000108774), RAB34 (ENSG00000109113), RAB5B (ENSG00000111540), RAB35 (ENSG00000111737), RAB23 (ENSG00000112210), DNAJC27 (ENSG00000115137), RAB29 (ENSG00000117280), RAB32 (ENSG00000118508), RAB14 (ENSG00000119396), RAB9B (ENSG00000123570), RAB9A (ENSG00000123595), RAB38 (ENSG00000123892), RAB22A (ENSG00000124209), RAB17 (ENSG00000124839), RAB2B (ENSG00000129472), RAB25 (ENSG00000132698), RAB33A (ENSG00000134594), RAB30 (ENSG00000137502), RAB1A (ENSG00000138069), RAB20 (ENSG00000139832), RAB15 (ENSG00000139998), RAB40B (ENSG00000141542), RAB13 (ENSG00000143545), RABL2A (ENSG00000144134), RAB5A (ENSG00000144566), RAB19 (ENSG00000146955)

Protein

Protein identifiers

Ras-related protein Rab-1B — Q9H0U4 (reviewed: Q9H0U4)

All UniProt accessions (2): Q9H0U4, E9PLD0

UniProt curated annotations — full annotation on UniProt →

Function. The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes. Rabs cycle between an inactive GDP-bound form and an active GTP-bound form that is able to recruit to membranes different set of downstream effectors directly responsible for vesicle formation, movement, tethering and fusion. Plays a role in the initial events of the autophagic vacuole development which take place at specialized regions of the endoplasmic reticulum. Regulates vesicular transport between the endoplasmic reticulum and successive Golgi compartments. Required to modulate the compacted morphology of the Golgi. Promotes the recruitment of lipid phosphatase MTMR6 to the endoplasmic reticulum-Golgi intermediate compartment.

Subunit / interactions. Interacts with MICAL1 and MICAL2. Interacts (in GTP-bound form) with MICALCL, MICAL1 and MILCAL3. Interacts with GDI1; the interaction requires the GDP-bound state. Interacts with CHM/REP1; the interaction requires the GDP-bound form and is necessary for prenylation by GGTase II. Interacts with RabGAP TBC1D20. Interacts (in GDP-bound form) with lipid phosphatase MTMR6 (via GRAM domain); the interaction regulates MTMR6 recruitment to the endoplasmic reticulum-Golgi intermediate compartment. Interacts (in GDP-bound form) with lipid phosphatase MTMR7. (Microbial infection) Interacts with L.pneumophila AnkX. Interacts with L.pneumophila Lem3. Interacts with L.pneumophila SidD. Interacts with L.pneumophila DrrA.

Subcellular location. Cytoplasm. Membrane. Preautophagosomal structure membrane. Perinuclear region.

Post-translational modifications. Prenylated; by GGTase II, only after interaction of the substrate with Rab escort protein 1 (REP1). (Microbial infection) AMPylation at Tyr-77 by L.pneumophila DrrA occurs in the switch 2 region and leads to moderate inactivation of the GTPase activity. It appears to prolong the lifetime of the GTP state of RAB1B by restricting access of GTPase effectors to switch 2 and blocking effector-stimulated GTP hydrolysis, thereby rendering RAB1B constitutively active. It is later de-AMPylated by L.pneumophila SidD, releasing RAB1B from bacterial phagosomes. (Microbial infection) Phosphocholinated at Ser-76 by L.pneumophila AnkX, leading to displace GDP dissociation inhibitors (GDI). Both GDP-bound and GTP-bound forms can be phosphocholinated. Dephosphocholinated by L.pneumophila Lem3, restoring accessibility to L.pneumophila GTPase effector LepB. (Microbial infection) Glycosylated by S.typhimurium protein Ssek3: arginine GlcNAcylation prevents GTPase activity, thereby disrupting vesicular protein transport from the endoplasmic reticulum (ER) to the Golgi compartment.

Activity regulation. Regulated by guanine nucleotide exchange factors (GEFs) which promote the exchange of bound GDP for free GTP. Regulated by GTPase activating proteins (GAPs) including TBC1D20 which increases the GTP hydrolysis activity. Inhibited by GDP dissociation inhibitors (GDIs).

Domain organisation. Switch I, switch II and the interswitch regions are characteristic of Rab GTPases and mediate the interactions with Rab downstream effectors. The switch regions undergo conformational changes upon nucleotide binding which drives interaction with specific sets of effector proteins, with most effectors only binding to GTP-bound Rab.

Miscellaneous. Rab-1B binds GTP and GDP and possesses low intrinsic GTPase activity.

Similarity. Belongs to the small GTPase superfamily. Rab family.

RefSeq proteins (1): NP_112243* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001806	Small_GTPase	Family
IPR005225	Small_GTP-bd	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR050227	Rab	Family
IPR057289	Rab1/Ypt1	Family

Pfam: PF00071

Enzyme classification (BRENDA):

• EC 3.6.5.2 — small monomeric GTPase (BRENDA: 49 organisms, 138 substrates, 55 inhibitors, 5 Km, 1 kcat entries)

Substrate kinetics (BRENDA)

1 substrates with measured Km, best-characterized 1. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
GTP	—	0

Catalyzed reactions (Rhea), 1 shown:

• GTP + H2O = GDP + phosphate + H(+) (RHEA:19669)

UniProt features (63 total): binding site 23, mutagenesis site 11, helix 8, strand 7, region of interest 4, modified residue 4, turn 3, lipid moiety-binding region 2, chain 1

Structure

Experimental structures (PDB)

9 structures.

PDB	Method	Resolution (Å)
3NKV	X-RAY DIFFRACTION	1.7
3JZA	X-RAY DIFFRACTION	1.8
8ALK	X-RAY DIFFRACTION	2.15
5SZH	X-RAY DIFFRACTION	2.3
5O74	X-RAY DIFFRACTION	2.5
4I1O	X-RAY DIFFRACTION	2.7
5SZK	X-RAY DIFFRACTION	2.8
6SKU	X-RAY DIFFRACTION	3.2
4HLQ	X-RAY DIFFRACTION	3.3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H0U4-F1	86.40	0.71

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (23): 22; 22; 23; 33; 34; 35; 36; 39; 40; 40; 63; 66 …

Post-translational modifications (6): 1, 76, 77, 201, 200, 201

Mutagenesis-validated functional residues (11):

Position	Phenotype
67	no effect on gdi1 binding. reduces prenylation in vitro, but not in vivo. no effect on interaction with rep1/chm; 100-fo
73	abolishes interaction with rep1/chm. no prenylation. much lower gdp/gtp ratio.
76	abolishes phosphocholination by legionella ankx.
77	abolishes ampylation by legionella drra.
78	abolishes interaction with rep1/chm and gdi1. no prenylation. much lower gdp/gtp ratio. no membrane association.
81	abolishes interaction with rep1/chm. no prenylation. lowers gdp/gtp ratio by half.
103	no effect on prenylation.
110	no effect on prenylation.
121	prevent formation of autophagosomes.
137	no effect on prenylation.
144	no effect on prenylation.

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-162658	Golgi Cisternae Pericentriolar Stack Reorganization
R-HSA-204005	COPII-mediated vesicle transport
R-HSA-6807878	COPI-mediated anterograde transport
R-HSA-6811434	COPI-dependent Golgi-to-ER retrograde traffic
R-HSA-8873719	RAB geranylgeranylation
R-HSA-8876198	RAB GEFs exchange GTP for GDP on RABs

MSigDB gene sets: 212 (showing top): GCACCTT_MIR18A_MIR18B, GOBP_ENDOTHELIAL_CELL_DEVELOPMENT, GOBP_EPITHELIUM_DEVELOPMENT, WWTAAGGC_UNKNOWN, TGCGCANK_UNKNOWN, GOBP_VACUOLE_ORGANIZATION, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_EPITHELIAL_CELL_DEVELOPMENT, GOBP_ESTABLISHMENT_OF_ENDOTHELIAL_INTESTINAL_BARRIER, LFA1_Q6, AAGCCAT_MIR135A_MIR135B, GCAAGGA_MIR502, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_REGULATION_OF_VACUOLE_ORGANIZATION, REACTOME_MEMBRANE_TRAFFICKING

GO Biological Process (9): autophagosome assembly (GO:0000045), intracellular protein transport (GO:0006886), endoplasmic reticulum to Golgi vesicle-mediated transport (GO:0006888), Golgi organization (GO:0007030), virion assembly (GO:0019068), positive regulation of glycoprotein metabolic process (GO:1903020), regulation of autophagosome assembly (GO:2000785), autophagy (GO:0006914), protein transport (GO:0015031)

GO Molecular Function (6): GTPase activity (GO:0003924), G protein activity (GO:0003925), GTP binding (GO:0005525), nucleotide binding (GO:0000166), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (13): Golgi membrane (GO:0000139), endoplasmic reticulum membrane (GO:0005789), Golgi apparatus (GO:0005794), cytosol (GO:0005829), endomembrane system (GO:0012505), transport vesicle (GO:0030133), endoplasmic reticulum-Golgi intermediate compartment membrane (GO:0033116), phagophore assembly site membrane (GO:0034045), perinuclear region of cytoplasm (GO:0048471), extracellular exosome (GO:0070062), cytoplasm (GO:0005737), endoplasmic reticulum-Golgi intermediate compartment (GO:0005793), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
ER to Golgi Anterograde Transport	2
Mitotic Prophase	1
Golgi-to-ER retrograde transport	1
Post-translational protein modification	1
Rab regulation of trafficking	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	5
cellular anatomical structure	5
intracellular protein localization	2
intracellular transport	2
bounding membrane of organelle	2
endomembrane system	2
intracellular membrane-bounded organelle	2
Atg12 activating enzyme activity	1
protein-phosphatidylethanolamide deconjugating activity	1
Atg12 conjugating enzyme activity	1
Atg12 ligase activity	1
organelle assembly	1
Atg1/ULK1 kinase complex assembly	1
autophagosome organization	1
protein transport	1
intercellular transport	1
Golgi vesicle transport	1
organelle organization	1
endomembrane system organization	1
viral process	1
viral life cycle	1
glycoprotein metabolic process	1
positive regulation of protein metabolic process	1
regulation of glycoprotein metabolic process	1
autophagosome assembly	1
regulation of vacuole organization	1
regulation of organelle assembly	1
catabolic process	1
transmembrane transport	1
process utilizing autophagic mechanism	1
transport	1
establishment of protein localization	1
ribonucleoside triphosphate phosphatase activity	1
GTPase activity	1
molecular function regulator activity	1
guanyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1

Protein interactions and networks

STRING

2303 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RAB1B	TBC1D20	Q96BZ9	916
RAB1B	GOLGA2	Q08379	892
RAB1B	PITPNC1	Q9UKF7	880
RAB1B	RUSC2	Q8N2Y8	866
RAB1B	LMAN1	P49257	851
RAB1B	RABIF	P47224	676
RAB1B	COPB1	P53618	663
RAB1B	LRPAP1	P30533	595
RAB1B	USO1	O60763	572
RAB1B	MICAL3	Q7RTP6	568
RAB1B	GOLGA5	Q8TBA6	560
RAB1B	TRAPPC8	Q9Y2L5	542
RAB1B	MTMR6	Q9Y217	537
RAB1B	MICAL1	Q8TDZ2	515
RAB1B	GBF1	Q92538	507

IntAct

127 interactions, top by confidence:

A	B	Type	Score
GDI1	RAB4A	psi-mi:“MI:0914”(association)	0.820
RABIF	RAB1B	psi-mi:“MI:0915”(physical association)	0.800
	LRRK2	psi-mi:“MI:0217”(phosphorylation reaction)	0.790
RABIF	RAB3A	psi-mi:“MI:0914”(association)	0.780
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
RAB1B	OCRL	psi-mi:“MI:0407”(direct interaction)	0.670
OCRL	RAB1B	psi-mi:“MI:0407”(direct interaction)	0.670
RAB8B	GDI1	psi-mi:“MI:0914”(association)	0.640
	RAB1B	psi-mi:“MI:0407”(direct interaction)	0.620
	LRRK2	psi-mi:“MI:0217”(phosphorylation reaction)	0.620
LRRK2	RAB1B	psi-mi:“MI:0217”(phosphorylation reaction)	0.590
RAB1B	RUSC2	psi-mi:“MI:0915”(physical association)	0.570
RUSC2	RAB1B	psi-mi:“MI:0915”(physical association)	0.570
GOLGA2	RAB1B	psi-mi:“MI:0915”(physical association)	0.550
PITPNC1	RAB1B	psi-mi:“MI:0915”(physical association)	0.540
PITPNC1	RAB1B	psi-mi:“MI:0403”(colocalization)	0.540
MAPT	KIF2A	psi-mi:“MI:0914”(association)	0.530
RAB1A	CHM	psi-mi:“MI:0914”(association)	0.530
RAB1B	CHM	psi-mi:“MI:0914”(association)	0.530
RABIF	RAB13	psi-mi:“MI:0914”(association)	0.530

BioGRID (653): RAB1B (Affinity Capture-MS), GDI1 (Affinity Capture-MS), GDI2 (Affinity Capture-MS), RAB1A (Affinity Capture-MS), RAB8B (Affinity Capture-MS), CHML (Affinity Capture-MS), CHM (Affinity Capture-MS), BZW2 (Affinity Capture-MS), RABGGTA (Affinity Capture-MS), RAB33B (Affinity Capture-MS), RAP1GDS1 (Affinity Capture-MS), RAB1B (Affinity Capture-MS), RAB1B (Affinity Capture-MS), ATP1A1 (Co-fractionation), ATP1A3 (Co-fractionation)

ESM2 similar proteins: E2RQ15, O01803, O23561, P05714, P10536, P16976, P20338, P28185, P28188, P31584, P36410, P36861, P40392, P51146, P56371, P57735, P61017, P61018, P61106, P61107, Q05737, Q06AU7, Q2HJH2, Q2TBH7, Q39571, Q40191, Q40520, Q40522, Q40523, Q40723, Q4R8X3, Q52NJ6, Q53B90, Q58DW6, Q5R8Z8, Q5RE13, Q5ZKU5, Q68EK7, Q8CG50, Q91V41

Diamond homologs: A1DZY4, A6QP66, A8NU18, C4YKT4, O08989, O14807, O35929, O88667, O93856, O94363, P01119, P03967, P08645, P08647, P0CY32, P10114, P10536, P11233, P11234, P15064, P17609, P22124, P22126, P22278, P22279, P22280, P28775, P32254, P36860, P36863, P48555, P59279, P61105, P61225, P61226, P61227, P62070, P62071, P63320, P63321

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 122 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
RAB geranylgeranylation	9	17.5×	6e-07
RAB GEFs exchange GTP for GDP on RABs	10	13.9×	6e-07
Translocation of SLC2A4 (GLUT4) to the plasma membrane	6	10.4×	3e-03
ER-Phagosome pathway	7	10.2×	1e-03

GO biological processes:

GO term	Partners	Fold	FDR
exocytosis	8	11.2×	6e-04
vesicle-mediated transport	8	7.1×	3e-03
endocytosis	8	7.0×	3e-03
protein transport	13	5.3×	6e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

23 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	17
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1007 predictions. Top by Δscore:

Variant	Effect	Δscore
11:66268689:GAATA:G	donor_gain	1.0000
11:66268690:AATA:A	donor_gain	1.0000
11:66268691:ATA:A	donor_gain	1.0000
11:66268691:ATAGT:A	donor_loss	1.0000
11:66268692:TA:T	donor_gain	1.0000
11:66268692:TAGT:T	donor_loss	1.0000
11:66268693:AGT:A	donor_loss	1.0000
11:66268694:G:GG	donor_gain	1.0000
11:66268695:T:A	donor_loss	1.0000
11:66268698:G:GG	donor_gain	1.0000
11:66268744:GGGCT:G	donor_gain	1.0000
11:66268745:GGCTG:G	donor_gain	1.0000
11:66271793:CCA:C	acceptor_loss	1.0000
11:66271794:CAG:C	acceptor_loss	1.0000
11:66271795:A:AG	acceptor_gain	1.0000
11:66271795:AGT:A	acceptor_gain	1.0000
11:66271796:G:GA	acceptor_gain	1.0000
11:66271796:GT:G	acceptor_gain	1.0000
11:66271796:GTG:G	acceptor_gain	1.0000
11:66271796:GTGA:G	acceptor_gain	1.0000
11:66271796:GTGAC:G	acceptor_gain	1.0000
11:66271867:GCT:G	donor_gain	1.0000
11:66271870:G:GG	donor_gain	1.0000
11:66271874:G:GG	donor_gain	1.0000
11:66272137:ATT:A	acceptor_gain	1.0000
11:66272137:ATTG:A	acceptor_gain	1.0000
11:66272139:T:A	acceptor_gain	1.0000
11:66272146:T:TA	acceptor_gain	1.0000
11:66272149:A:AG	acceptor_gain	1.0000
11:66272150:C:G	acceptor_gain	1.0000

AlphaMissense

1317 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:66271825:G:C	G15R	1.000
11:66271825:G:T	G15C	1.000
11:66271826:G:A	G15D	1.000
11:66271826:G:T	G15V	1.000
11:66271840:G:C	G20R	1.000
11:66271840:G:T	G20C	1.000
11:66271841:G:A	G20D	1.000
11:66271841:G:T	G20V	1.000
11:66271843:A:C	K21Q	1.000
11:66271844:A:T	K21M	1.000
11:66271845:G:C	K21N	1.000
11:66271845:G:T	K21N	1.000
11:66271847:C:T	S22L	1.000
11:66271856:T:C	L25P	1.000
11:66271859:T:C	L26P	1.000
11:66272184:A:C	S39R	1.000
11:66272186:C:A	S39R	1.000
11:66272186:C:G	S39R	1.000
11:66272188:C:T	T40I	1.000
11:66272191:T:A	I41N	1.000
11:66272193:G:A	G42R	1.000
11:66272193:G:C	G42R	1.000
11:66272193:G:T	G42W	1.000
11:66272194:G:A	G42E	1.000
11:66272194:G:T	G42V	1.000
11:66272199:G:C	D44H	1.000
11:66272200:A:G	D44G	1.000
11:66272200:A:T	D44V	1.000
11:66272202:T:C	F45L	1.000
11:66272203:T:C	F45S	1.000

dbSNP variants (sampled 300 via entrez): RS1000191800 (11:66271613 A>G), RS1000302602 (11:66273055 G>A), RS1000423122 (11:66267715 T>C,G), RS1000529268 (11:66273167 C>T), RS1000628682 (11:66271383 G>T), RS1001003665 (11:66271626 A>G), RS1001305418 (11:66277729 G>A,T), RS1001448336 (11:66267563 A>G), RS1001599826 (11:66268004 C>A), RS1001690799 (11:66272521 T>G), RS1001829341 (11:66267750 A>C), RS1001863620 (11:66272563 G>A), RS1002029262 (11:66267781 G>A), RS1002096887 (11:66274062 C>T), RS1002398632 (11:66271954 G>A,T)

Disease associations

OMIM: gene MIM:612565 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST001241_12	Bipolar disorder	2.000000e-07
GCST008103_21	Bipolar disorder	2.000000e-08

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

46 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases abundance, increases expression	4
Tobacco Smoke Pollution	affects expression, increases expression	2
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
sodium arsenate	decreases expression	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, affects localization, increases expression	1
arsenite	increases abundance, increases expression	1
cobaltous chloride	decreases expression	1
perfluorooctanoic acid	decreases expression	1
ochratoxin A	affects binding	1
cupric oxide	decreases expression	1
ochratoxin B	affects binding	1
di-n-butylphosphoric acid	affects expression	1
monomethylarsonous acid	increases expression	1
nutlin 3	affects cotreatment, increases secretion	1
ICG 001	decreases expression	1
bisphenol B	increases expression	1
MT19c compound	decreases expression	1
3-(2-hydroxy-4-(2-methylnonan-2-yl)phenyl)cyclohexan-1-ol	increases expression	1
bisphenol AF	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Rosiglitazone	increases expression	1
Temozolomide	decreases expression	1
Sunitinib	decreases expression	1
Azacitidine	increases expression	1
Benzo(a)pyrene	decreases expression	1
Caffeine	decreases phosphorylation	1
Dactinomycin	increases secretion, affects cotreatment	1
Bucladesine	affects cotreatment, increases expression	1
Diuron	decreases expression	1

Cellosaurus cell lines

3 cell lines: 2 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3FL	Abcam HEK293T RAB1B KO	Transformed cell line	Female
CVCL_TH99	HAP1 RAB1B (-) 1	Cancer cell line	Male
CVCL_TI00	HAP1 RAB1B (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.